- Q1 2024 Embla Medical hf Earnings Call TranscriptApr 23, 2024kr30.7 (+1.99%)Earnings
- Q4 2023 Ossur hf Earnings Call TranscriptJan 30, 2024kr29.65 (+4.40%)Earnings
- Q3 2023 Ossur hf Earnings Call TranscriptOct 24, 2023kr29.3 (+2.99%)Earnings
- Q2 2023 Ossur hf Earnings Call TranscriptJul 25, 2023kr32.4 (+1.73%)Earnings
- Q1 2023 Ossur hf Earnings Call TranscriptApr 25, 2023kr30.75 (-1.76%)Earnings
- Ossur hf Corporate Analyst Meeting TranscriptMar 30, 2023
- Q4 2022 Ossur hf Earnings Call TranscriptJan 31, 2023Earnings
- Q3 2022 Ossur hf Earnings Call TranscriptOct 25, 2022kr32.95 (-1.79%)Earnings
- Q2 2022 Ossur hf Earnings Call TranscriptJul 21, 2022kr31.5 (+5.00%)Earnings
- Preliminary Q2 2022 Ossur hf Earnings Call TranscriptJul 18, 2022kr29.6Earnings
- Q1 2022 Ossur hf Earnings Call TranscriptApr 26, 2022kr36.4 (-5.45%)Earnings
- Q4 2021 Ossur hf Earnings Call TranscriptFeb 01, 2022kr40.6 (+4.10%)Earnings
- Q3 2021 Ossur hf Earnings Call TranscriptOct 26, 2021kr43.2Earnings
- Q2 2021 Ossur hf Earnings Call TranscriptJul 22, 2021kr48 (+1.27%)Earnings
- Q1 2021 Ossur hf Earnings Call TranscriptApr 27, 2021kr47.25 (+2.05%)Earnings
- Q4 2020 Ossur hf Earnings Call TranscriptFeb 02, 2021kr46.25 (+0.22%)Earnings
- Q3 2020 Ossur hf Earnings Call TranscriptOct 27, 2020kr42 (-2.33%)Earnings
- Q2 2020 Ossur hf Earnings Call TranscriptJul 23, 2020kr44.3 (+0.23%)Earnings
- Q1 2020 Ossur hf Earnings Call TranscriptApr 30, 2020kr43.65 (+1.51%)Earnings
- Q4 2019 Ossur hf Earnings Call TranscriptFeb 04, 2020kr49.55 (-0.10%)Earnings
- Full Year 2019 Ossur hf Guidance Call TranscriptJan 14, 2020
- Q3 2019 Ossur hf Earnings Call TranscriptOct 22, 2019kr45.5 (+1.11%)Earnings
- Q2 2019 Ossur hf Earnings Call TranscriptJul 25, 2019kr45.95 (+5.88%)Earnings
- Q1 2019 Ossur hf Earnings Call TranscriptApr 30, 2019kr37.3 (+5.97%)Earnings
Full Year 2019 Ossur hf Guidance Call Transcript
&
Yes, thank you and good afternoon. Thank you for joining, all, us on this conference call where we will cover the revised guidance for 2019 based on the preliminary figures for the fourth quarter of 2019.
My name is Jón Sigurdsson. And with me here today is Sveinn Sölvason, our CFO. We will begin with a short overview, after which we will have a question-and-answer session.
We are today revising our financial guiding for the full year of 2019 due to the lower-than-expected prosthetics sales in the fourth quarter. Preliminary results suggest that sales in the fourth quarter of 2019 amounted to $180 million, corresponding to 1% organic growth and 10% local currency growth. Sales for the full year of 2019 therefore amounted to $686 million, corresponding to 5% organic growth and 16% local currency growth.
EBITDA before special items for the fourth quarter of 2019 amounted to $37 million or 21% of sales. EBITDA before special items for the full year 2019 amounted to $150 million or 22
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)